Company Analysis
Sign in

Rhythm Pharmaceuticals, Inc. (RYTM)

Nasdaq: RYTM · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2015
Full chart Alerts Compare
Grade6.2
◀ Past 7.7● Present 5.9▶ Future 5.2
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

11 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Rhythm Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
11
11 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and 1 in 2023
Applications published
22
5 of them in 2025
Names they are printed under
3
its own name, a former name
By yearGrantedApplications published
'14'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals5
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
RHYTHM PHARMACEUTICALS, INC. its own name
named as the applicant on its applications, in US
0 granted
18 published
RHYTHM PHARMACEUTICALS, INC. its own name
US, as the owner printed on each patent
11 granted
1 published
Rhythm Metabolic, Inc. a former name
named as the applicant on its applications, in US
0 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 29, 202512,285,460Pharmaceutical compositionsPharmaceuticalsRHYTHM PHARMACEUTICALS, INC.
Apr 1, 202512,263,202Method of treating melanocortin-4 receptor pathway-associated disordersPharmaceuticalsRHYTHM PHARMACEUTICALS, INC.
Sep 3, 202412,077,612Peptide compositionsPharmaceuticalsRHYTHM PHARMACEUTICALS, INC.
Jul 18, 202311,702,448Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriersBiotechnologyRHYTHM PHARMACEUTICALS, INC.
Sep 28, 202111,129,869Pharmaceutical compositionsPharmaceuticalsRHYTHM PHARMACEUTICALS, INC.
Mar 30, 202110,960,046Method of treating melanocortin-4 receptor pathway-associated disordersPharmaceuticalsRHYTHM PHARMACEUTICALS, INC.
Mar 23, 202110,954,268Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriersBiotechnologyRHYTHM PHARMACEUTICALS, INC.
Dec 8, 202010,858,399Peptide compositionsPharmaceuticalsRHYTHM PHARMACEUTICALS, INC.
Feb 5, 201910,196,425Peptide compositionsPharmaceuticalsRHYTHM PHARMACEUTICALS, INC.
Jan 1, 201910,167,312Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriersBiotechnologyRHYTHM PHARMACEUTICALS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0360142NOVEL ATP-SENSITIVE POTASSIUM CHANNEL POTENTIATORS, THEIR PREPARATION AND USEOrganic fine chemistryRHYTHM PHARMACEUTICALS, INC.
Jun 19, 20252025/0195606METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERSPharmaceuticalsRHYTHM PHARMACEUTICALS, INC.
Jun 12, 20252025/0188124PEPTIDE COMPOSITIONSPharmaceuticalsRHYTHM PHARMACEUTICALS, INC.
Jun 12, 20252025/0186536SUSTAINED RELEASE PEPTIDE FORMULATIONSPharmaceuticalsRHYTHM PHARMACEUTICALS, INC.
Mar 13, 20252025/0082717COMPOSITIONS FOR TREATING KIDNEY DISEASEPharmaceuticalsRHYTHM PHARMACEUTICALS, INC.
Jun 13, 20242024/0190914METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERSBiotechnologyRHYTHM PHARMACEUTICALS, INC.
Feb 22, 20242024/0058414METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERSPharmaceuticalsRHYTHM PHARMACEUTICALS, INC.
Jul 21, 20222022/0226425METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERSPharmaceuticalsRHYTHM PHARMACEUTICALS, INC.
May 26, 20222022/0160818PHARMACEUTICAL COMPOSITIONSPharmaceuticalsRHYTHM PHARMACEUTICALS, INC. · patent 12,285,460 granted from it
Jun 10, 20212021/0169970METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERSPharmaceuticalsRHYTHM PHARMACEUTICALS, INC. · patent 12,263,202 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Biotechnology 1 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton RYTM · research, not advice